Compare Amgen, Inc. (AMGN) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Bill.com Holdings Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Bill.com Holdings Inc trades at $41.2 (market cap $4.12B). The key difference: Amgen, Inc. is far larger — about 47.6× Bill.com Holdings Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| AMGN | BILL | |
|---|---|---|
Market Cap | $196.12B | $4.12B |
Sector | Health | Technology |
52-Week High | $388.16 | $56.32 |
52-Week Low | $271.18 | $31.96 |
Enterprise Value | $241.41B | $3.83B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BILL Holdings trades at $41.36, up 2.07% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical outlook with support at $39 and resistance at $42. Revenue growth accelerated to $1.46 billion in 2025, though net margins remain thin at 0.01%. Recent leadership changes and a $1 billion buyback program signal confidence in future growth.
Outlook remains positive with 56% analyst buy ratings and a $48 consensus target suggesting 16% upside. Key risks include high valuation (P/E 214), competitive pressures in SMB software, and sensitivity to interest rate changes. The company's transition to profitability and AI integration present opportunities if execution continues improving.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
